A Study of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy for Patients With KRAS Positive or Squamous Cell Non-Small Cell Lung Cancer

Clinical trial NCT02283320 · COMPLETED

Trial details

NCT number: NCT02283320
Sponsor: BIND Therapeutics
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

KRAS Positive Patients With Non-small Cell Lung Cancer Squamous Cell Non-small Cell Lung Cancer

Start date: 2014-09-01
Primary completion: 2016-04-01
Enrollment: 69

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.